Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gait training protocol focused on impairment level vs gait training protocol focused on task level Phantom limb pain frequency · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motor imaging vs usual care Adverse events · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motor imaging vs usual care Mortality – all causes · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motor imaging vs usual care Quality of life · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Motor imaging vs usual care Mobility assessment · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | 1 study · 8 participants | Very low |
Motor imaging vs usual care Phantom limb pain frequency · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Gait training protocol focused on impairment level vs gait training protocol focused on task level Prosthesis use · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Ungraded |
Gait training protocol focused on impairment level vs gait training protocol focused on task level Adverse events – pain · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Gait training protocol focused on impairment level vs gait training protocol focused on task level Mortality – all cause · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Limb salvage rate · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | RR 0.84 [0.49, 1.45] | 2 studies · 936 participants | Low |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) All‐cause mortality · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) Functional walking ability · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) Clinical severity scales · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) Quality of life scores · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Vessel or graft secondary patency · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | RR 0.92 [0.67, 1.26] | 3 studies · 1092 participants | Low |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) All‐cause mortality · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | RR 1.11 [0.7, 1.74] | 1 study · 594 participants | Low |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Functional walking ability · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Clinical severity scales · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Quality of life scores · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | 1 study · 594 participants | Low |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) Limb salvage rate · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) Vessel or graft secondary patency · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | RR 0.83 [0.19, 3.51] | 1 study · 156 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 0.6 [0.41, 0.87] | 11 studies · 1437 participants | Moderate |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Acute coronary syndrome (such as MI or coronary thrombus) (up to 7 weeks) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Duration of fever (days) (acute phase) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 4 studies · 992 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Need for additional treatment (up to 6 months) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 0.29 [0.1, 0.88] | 4 studies · 1125 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Length of hospital stay (days) (up to 28 days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 3 studies · 752 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Mortality (all‐cause) (up to 7 weeks) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 1 study · 549 participants | Moderate |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Incidence of CAAs (acute phase) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 0.6 [0.24, 1.48] | 2 studies · 140 participants | Very low |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Incidence of any adverse effects after treatment initiation (up to 3 months) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 4.18 [0.19, 89.48] | 1 study · 90 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Acute coronary syndrome (such as MI or coronary thrombus) (up to 3 months) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 1 study · 90 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Duration of fever (days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 2 studies · 140 participants | Very low |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Need for additional treatment · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Incidence of any adverse effects after treatment initiation (from 30 days to 30 months) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 0.57 [0.17, 1.89] | 10 studies · 1376 participants | Very low |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Length of hospital stay (days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 1 study · 90 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Acute coronary syndrome (such as MI or coronary thrombus) (to 30 months) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 2 studies · 202 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Duration of fever (days) (acute phase) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | 3 studies · 307 participants | Moderate |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Need for additional treatment (up to 30 or 60 days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 0.27 [0.05, 1.57] | 3 studies · 272 participants | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Length of hospital stay (days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Mortality (all‐cause) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | Low |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 0.6 [0.4, 0.89] | 8 studies · 1824 participants | Moderate |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | OR 1.11 [0.52, 2.37] | 6 studies · 1659 participants | Low |
Anticoagulant vs placebo or no treatment All‐cause mortality · non‐hospitalised people with COVID‐19 Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 (2023) · Cochrane | RR 0.36 [0.04, 3.61] | 5 studies · 1777 participants | Low |
Anticoagulant vs different dose of the same anticoagulant Major bleeding · non‐hospitalised people with COVID‐19 Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 (2023) · Cochrane | no estimate extracted | 1 study · 278 participants | Moderate |
Anticoagulant vs different dose of the same anticoagulant Deep vein thrombosis · non‐hospitalised people with COVID‐19 Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant vs different dose of the same anticoagulant Pulmonary embolism · non‐hospitalised people with COVID‐19 Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant vs different dose of the same anticoagulant Need for hospitalisation · non‐hospitalised people with COVID‐19 Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 (2023) · Cochrane | RR 1.89 [0.17, 20.58] | 1 study · 278 participants | Low |
Anticoagulant vs different dose of the same anticoagulant Adverse events (minor bleeding) · non‐hospitalised people with COVID‐19 Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 (2023) · Cochrane | RR 0.47 [0.09, 2.54] | 1 study · 278 participants | Low |